Effect of intracameral Bevacizumab injection on corneal endothelial cells: an in vivo evaluation

Effect of intracameral Bevacizumab injection on corneal endothelial cells in patients with iris neovascularization: an in vivo evaluation

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000716268

Enrollment

Registered

2009-08-20

Start date

2008-12-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is to evaluate the effect of a drug that decreases the growth of immature blood vessels that cause complications in the eye due to some diseases like diabetes. Its effect has been studied on the deep layers of the eye when injected in front of the retina, but this study evaluates its potential toxicity on the front side of the eye when injected just behind the cornea.

Interventions

Single injection of intracameral Bevacizumab at a concentration of 1.25 mg/0.05 mL for the treatment of iris neovascularization

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

38 Years to 60 Years

Healthy volunteers

Inclusion criteria

patients with iris neovascularization

Exclusion criteria

corneal edema or preoperative corneal endothelial desnity<1500 cells/mm2

Outcome results